[{"id":"f031d34d-933f-4bf9-837f-6a5b73d3ea3f","acronym":"KontRASt-02","url":"https://clinicaltrials.gov/study/NCT05132075","created_at":"2021-11-24T18:55:29.286Z","updated_at":"2025-02-25T13:40:42.926Z","phase":"Phase 3","brief_title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05132075 - KontRASt-02","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 06/23/2022","start_date":" 06/23/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-21"},{"id":"0722b240-7848-480e-91ab-a7a7c502ac66","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445843","created_at":"2022-07-06T14:54:25.537Z","updated_at":"2024-07-02T16:34:27.361Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression \u003c 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","source_id_and_acronym":"NCT05445843","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • KRAS • STK11","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression","tags":["PD-L1 • KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 11/02/2026","primary_completion_date":" 11/02/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-06-11"},{"id":"fa46a890-7098-41a4-a73e-faad6ef1e43e","acronym":"KontRASt-01","url":"https://clinicaltrials.gov/study/NCT04699188","created_at":"2021-01-19T20:50:07.332Z","updated_at":"2024-07-02T16:34:58.896Z","phase":"Phase 1/2","brief_title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","source_id_and_acronym":"NCT04699188 - KontRASt-01","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • batoprotafib (TNO155) • opnurasib (JDQ443)"],"overall_status":"Recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 01/08/2027","primary_completion_date":" 01/08/2027","study_txt":" Completion: 01/08/2027","study_completion_date":" 01/08/2027","last_update_posted":"2024-06-04"},{"id":"b989ed96-6405-48a0-a6ff-5c01d40b48c3","acronym":"STRIDER","url":"https://clinicaltrials.gov/study/NCT05999357","created_at":"2023-08-21T16:09:25.818Z","updated_at":"2025-02-25T15:54:52.477Z","phase":"Phase 2","brief_title":"JDQ443 for KRAS G12C NSCLC Brain Metastases","source_id_and_acronym":"NCT05999357 - STRIDER","lead_sponsor":"Maastricht University Medical Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opnurasib (JDQ443)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/15/2024","start_date":" 04/15/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-05-29"},{"id":"c4e12387-d4df-4616-9eae-dc4f5f7a2130","acronym":"KontRASt-03","url":"https://clinicaltrials.gov/study/NCT05358249","created_at":"2022-05-03T14:53:55.479Z","updated_at":"2024-07-02T16:35:20.052Z","phase":"Phase 1/2","brief_title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","source_id_and_acronym":"NCT05358249 - KontRASt-03","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mekinist (trametinib) • Kisqali (ribociclib) • opnurasib (JDQ443)"],"overall_status":"Recruiting","enrollment":" Enrollment 346","initiation":"Initiation: 10/24/2022","start_date":" 10/24/2022","primary_txt":" Primary completion: 05/05/2027","primary_completion_date":" 05/05/2027","study_txt":" Completion: 06/16/2027","study_completion_date":" 06/16/2027","last_update_posted":"2024-02-09"}]